
    
      Eleven subjects will be enrolled into one of four cohorts: Cohort A (KRAS mutation, wild type
      INK4a/ARF and wildtype p53), Cohort B (KRAS mutation, INK4s/ARF mutation and wild type p53),
      Cohort C (KRAS mutation, wild type INK4a/ARF and p53 mutation), and Cohort D (KRAS mutation,
      INK4a/ARF mutation and p53 mutation). If >/= 4 patients demonstrate PFS at 12 weeks in each
      cohort, an additional 23 subjects will be enrolled.
    
  